Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Tribute Pharmaceuticals Canada Inc. | tbuff_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 25, 2014
Tribute Pharmaceuticals Canada Inc.
(Exact name of registrant as specified in its charter)
|
Ontario, Canada
|
001-31198
|
Not Applicable
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
151 Steeles Avenue East, Milton, Ontario, Canada L9T 1Y1
(Address of principal executive offices) (Zip Code)
(519) 434-1540
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act.
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
Item 7.01. Regulation FD Disclosure.
On September 25, 2014, Tribute Pharmaceuticals Canada Inc. (the “Company”) issued a press release with respect to the receipt by the Company of an additional patent from the U.S. Patent and Trademark Office for intellectual property that is central to one of the Company’s lead products, Uracyst®. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
(d) Exhibits
|
Exhibit No.
|
Description
|
|
|
Tribute Pharmaceuticals Canada Inc. Press Release, dated September 25, 2014
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TRIBUTE PHARMACEUTICALS CANADA INC.
|
|||
|
Date: September 25, 2014
|
By:
|
/s/ Scott Langille | |
|
Name: Scott Langille
|
|||
|
Title: Chief Financial Officer
|
|||
3
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
Tribute Pharmaceuticals Canada Inc. Press Release, dated September 25, 2014
|
4